| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Alloimperatorin targets cancer cells through apoptosis induction, cell cycle disruption, and inhibition of cell migration. It also exhibits urease inhibitory activity (IC₅₀ = 27.5 μM). Its targets include pathways involved in oxidative stress, inflammation, and apoptosis regulation.
|
|---|---|
| ln Vitro |
Alloimperatorin exhibits in vitro antitumor activity against multiple cancer cell lines, including HL-60 acute myeloid leukemia (IC₅₀ = 32.1 μM for its epoxide derivative vs. 128 μM for the parent compound) and HeLa cervical cancer cells (IC₅₀ = 116.9 μM). It induces apoptosis, cell cycle disruption, and inhibits cell migration. It also demonstrates antioxidative, anti-inflammatory, and antimicrobial activities.
|
| ln Vivo |
Alloimperatorin demonstrates anti-oxidative, anti-inflammatory, and anti-apoptotic effects in rodent models of drug-induced gastric ulceration and hepatorenal toxicity, with gastroprotective efficacy at 25 mg/kg in NSAID-induced injury models.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays for Alloimperatorin involve incubating the compound with urease enzyme and measuring activity using colorimetric or spectrophotometric methods to determine IC₅₀ values. Binding affinity to target proteins can be assessed using surface plasmon resonance or isothermal titration calorimetry.
|
| Cell Assay |
In vitro cell-based assays use HL-60 leukemia cells, HeLa cervical cancer cells, or other cancer cell lines cultured in appropriate media. Cells are treated with Alloimperatorin at varying concentrations for 24-72 hours, and cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by Annexin V/PI staining and flow cytometry, cell cycle analysis by propidium iodide staining, and cell migration by wound-healing or transwell assays.
|
| Animal Protocol |
In vivo animal studies employ rodent models such as NSAID-induced gastric ulceration or hepatorenal toxicity models. Alloimperatorin is administered orally (e.g., 25 mg/kg), followed by assessment of gastric tissue damage, oxidative stress markers, inflammatory cytokines, and histopathological examination of liver and kidney tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Alloimperatorin include a calculated XLogP3 of 3.90 and a topological polar surface area of 59.70 Ų, suggesting moderate lipophilicity and potential for membrane permeability. DMSO solubility is 83.33 mg/mL (308.31 mM). Detailed ADME data are limited; further studies are needed.
|
| Toxicity/Toxicokinetics |
Acute toxicity of Alloimperatorin appears low based on its use in rodent studies at 25 mg/kg without reported mortality. The compound photosensitizes hemolysis of erythrocytes. Comprehensive toxicological profiling is required for therapeutic development.
|
| References |
|
| Additional Infomation |
Alloimperatorin is a member of the psoralen family. It has been reported to exist in Angelica taiwanensis, Longan fusiforme, and other organisms with relevant data.
Alloimperatorin is a natural furanocoumarin used in cancer research, particularly for studying apoptosis and cell cycle regulation in leukemia and cervical cancer models. It is also studied for gastroprotective and anti-inflammatory applications. Not approved for clinical use; intended for research purposes only. |
| Molecular Formula |
C16H14O4
|
|---|---|
| Molecular Weight |
270.2800
|
| Exact Mass |
270.089
|
| CAS # |
642-05-7
|
| PubChem CID |
69502
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.298g/cm3
|
| Boiling Point |
476.1ºC at 760 mmHg
|
| Melting Point |
224-225ºC
|
| Flash Point |
241.8ºC
|
| Index of Refraction |
1.641
|
| LogP |
3.753
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
449
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KDXVVZMYSLWJMA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14O4/c1-9(2)3-4-10-11-5-6-13(17)20-16(11)14(18)15-12(10)7-8-19-15/h3,5-8,18H,4H2,1-2H3
|
| Chemical Name |
9-hydroxy-4-(3-methylbut-2-enyl)furo[3,2-g]chromen-7-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~308.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6999 mL | 18.4993 mL | 36.9987 mL | |
| 5 mM | 0.7400 mL | 3.6999 mL | 7.3997 mL | |
| 10 mM | 0.3700 mL | 1.8499 mL | 3.6999 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
